Barry, OppHub America Desk · · Source: prnewswire-all
CAPR Investigated for Securities Fraud Following FDA Review (After-Hours)
💡 If you are an investor who experienced losses with Capricor Therapeutics, Inc. ($CAPR) and believe it is related to the recent stock performance, you may wish to contact legal counsel to understand your options.
Capricor Therapeutics (NASDAQ: CAPR) faces a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP, prompting concern for investors following a significant stock decline. The probe initiated after the U.S. Food and Drug Administration released critical briefing documents concerning Capricor's cell therapy ahead of its advisory committee meeting.
[MARKET BIAS: HIGH_VOLATILITY] [SESSION: AFTER-HOURS] [CATALYST: Regulatory Review & Securities Investigation]
Capricor Therapeutics (NASDAQ: CAPR) is under a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP, raising concerns for investors after its stock saw a substantial decline this week. The investigation commenced following the U.S. Food and Drug Administration's release of briefing documents that raised questions about Capricor's cell therapy, deramiocel, ahead of a key advisory committee meeting.
### Money Play If you are an investor who experienced losses with Capricor Therapeutics, Inc. ($CAPR) and believe it is related to the recent stock performance, you may wish to contact legal counsel to understand your options.
## Catalyst Analysis: Regulatory Scrutiny and Data Integrity Concerns The core of the investigation stems from the FDA's critical review of Capricor's deramiocel therapy, designed for a heart condition linked to Duchenne muscular dystrophy. On Monday, July 27, 2026, the FDA's briefing documents questioned Capricor's methodology for measuring post-trial results, stating the conversion from raw change to percent change and back was not scientifically justified and reduced accuracy. These documents concluded that deramiocel's benefit-risk assessment appeared unfavorable without evidence of effectiveness. Following this news, Capricor's stock declined 64.5% on July 27, 2026.
A subsequent advisory committee meeting on Wednesday, July 29, 2026, where the FDA held a Tissue and Gene Therapies Advisory Committee review of deramiocel, further impacted the stock, which fell an additional 6.08% on that day.
## Technical Analysis & Key Risk Watch Capricor Therapeutics ($CAPR) closed Wednesday, July 29, 2026, at $6.57. With an RSI14 of 17.2, the stock is deeply oversold, suggesting a potential for an oversold bounce or further capitulation given the regulatory and legal overhangs. Investors will monitor any further regulatory actions or developments in the securities fraud investigation. Key support levels may be tested if negative sentiment persists, while any positive news could trigger a short-squeeze given the current technical position.
## Impact on Related Tickers While the direct impact is on Capricor Therapeutics, similar regulatory scrutiny or legal actions can create sector-wide cautious sentiment, particularly within the biotechnology and pharmaceutical industries focused on advanced therapies.
Based on reporting from prnewswire-all.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: July 29, 2026 at 7:56 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
biotech regulatory risk
A biotech company is facing a legal investigation after government health regulators released negative reports about its experimental medicine. People who bought the stock lost money and are now looking at their legal and financial choices.
What changed
Capricor Therapeutics ($CAPR) is under investigation for securities fraud following unfavorable FDA regulatory review documents.
Who wins / who loses
Law firms and short sellers benefit from the scrutiny, while long-term shareholders and the company suffer heavy losses.
Time horizon
Think in terms of next few days.
Confidence & best fit
high confidence · Active trader
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $CAPRStay away — for now
The company whose medicine was criticized by regulators is now being investigated, making its stock very risky to hold.
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Options are too unpredictable and expensive right now because of the sudden news; beginners should stay away.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Consulting legal counsel regarding potential class-action participation for verified stock losses.
What would break this thesis
- FDA reverses stance or advisory committee issues a surprisingly positive recommendation for deramiocel.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.